AUPH
Aurinia Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.13B
P/E Ratio
7.73
EPS
$2.07
Beta
1.52
52W High
$16.54
52W Low
$6.83
50-Day MA
$14.53
200-Day MA
$13.05
Dividend Yield
—
Profit Margin
101.50%
Forward P/E
22.94
PEG Ratio
0.00
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Fundamentals
| Revenue (TTM) | $283.06M |
| Gross Profit (TTM) | $217.88M |
| EBITDA | $135.71M |
| Operating Margin | 55.70% |
| Return on Equity | 59.90% |
| Return on Assets | 11.20% |
| Revenue/Share (TTM) | $2.11 |
| Book Value | $4.39 |
| Price-to-Book | 3.57 |
| Price-to-Sales (TTM) | 7.52 |
| EV/Revenue | 6.19 |
| EV/EBITDA | 12.71 |
| Quarterly Earnings Growth (YoY) | 15073.00% |
| Quarterly Revenue Growth (YoY) | 28.80% |
| Shares Outstanding | $132.97M |
| Float | $128.74M |
| % Insiders | 6.71% |
| % Institutions | 55.69% |
Analyst Ratings
Consensus ($17.00 target)
4
Buy3
HoldData last updated: 4/7/2026